Revolutionary Advances in Alzheimer’s: Innovative Amyloid Diagnostic Strategies Unveiled
A research group at LMU University Hospital is exploring better ways to diagnose Alzheimer’s disease. New drugs are set to launch in Germany to slow the disease’s progression. On November 14, 2024, the European Medicines Agency approved Lecanemab, a drug that targets amyloid plaques in the brain. A key challenge is diagnosing these plaques effectively and affordably in patients showing mild cognitive impairment or mild dementia.
The study, led by Professor Matthias Brendel and his colleagues, provides insights that could improve patient treatment. Their findings are published in the journal Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring.
Methods for Diagnosis
Doctors currently have two approved methods to detect amyloid plaques in Alzheimer’s patients:
-
Cerebrospinal Fluid (CSF) Analysis: This method requires a spinal tap, which is invasive and poses rare complications. It may not be suitable for patients on blood thinners and does not provide direct quantitative data on amyloid deposits.
- Positron Emission Tomography (PET): This non-invasive imaging technique offers direct evidence of amyloid deposits but costs between 1,500 and 3,000 euros per scan. It’s often not covered by health insurance, making it less accessible.
To compare the two methods, researchers analyzed data from over 400 patients suspected of having Alzheimer’s disease. Each patient underwent both CSF analysis and PET scans between 2013 and 2024.
The study found that:
- Patients with CSF amyloid levels above 7.1 often had normal PET scans.
- Patients with levels below 5.5 typically had abnormal PET results.
- A significant number of patients had CSF levels between 5.5 and 7.1, leading to uncertainty. Half of these patients had abnormal PET scans, indicating that CSF alone may not be reliable.
The researchers validated these results with a separate group at the University of Vienna, confirming their reliability.
Implications for Clinical Practice
As new amyloid-targeting drugs gain approval, these study findings could reshape diagnostic practices. When possible, PET scans would be the preferred diagnostic method. However, many patients currently have better access to CSF analysis in Germany.
Professor Brendel suggests that around 70 to 80 percent of patients could first receive a CSF analysis. Only those with ambiguous results in the gray area would need a follow-up PET scan. As the cost of PET scans decreases and access improves, it may become the primary diagnostic method, preventing the need for both tests in many cases. This approach aims to streamline diagnostics for better patient care.